DK2457904T3 - Methods for the synthesis and / or purification of the compounds diaminophenothiazinium - Google Patents
Methods for the synthesis and / or purification of the compounds diaminophenothiazinium Download PDFInfo
- Publication number
- DK2457904T3 DK2457904T3 DK11173334.1T DK11173334T DK2457904T3 DK 2457904 T3 DK2457904 T3 DK 2457904T3 DK 11173334 T DK11173334 T DK 11173334T DK 2457904 T3 DK2457904 T3 DK 2457904T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- acylated
- arc
- precursor
- deacylated
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 510
- 238000000034 method Methods 0.000 title claims description 215
- 230000015572 biosynthetic process Effects 0.000 title claims description 101
- 238000003786 synthesis reaction Methods 0.000 title claims description 100
- 238000000746 purification Methods 0.000 title claims description 93
- KPYHKEZPEDJERZ-UHFFFAOYSA-N 10h-phenothiazine-1,2-diamine Chemical compound C1=CC=C2NC3=C(N)C(N)=CC=C3SC2=C1 KPYHKEZPEDJERZ-UHFFFAOYSA-N 0.000 title description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 293
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 217
- 239000002243 precursor Substances 0.000 claims description 189
- -1 diaminophenothiazine compound Chemical class 0.000 claims description 151
- 238000011144 upstream manufacturing Methods 0.000 claims description 84
- 230000001590 oxidative effect Effects 0.000 claims description 81
- 238000011282 treatment Methods 0.000 claims description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- 229910001868 water Inorganic materials 0.000 claims description 53
- 239000002904 solvent Substances 0.000 claims description 33
- 239000000047 product Substances 0.000 claims description 28
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 22
- JEOGFTYLESYHAM-UHFFFAOYSA-N 1-[3,7-bis(dimethylamino)phenothiazin-10-yl]ethanone Chemical compound C1=C(N(C)C)C=C2SC3=CC(N(C)C)=CC=C3N(C(C)=O)C2=C1 JEOGFTYLESYHAM-UHFFFAOYSA-N 0.000 claims description 19
- 238000001953 recrystallisation Methods 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 14
- 238000001556 precipitation Methods 0.000 claims description 13
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 7
- QTWZICCBKBYHDM-UHFFFAOYSA-N leucomethylene blue Chemical compound C1=C(N(C)C)C=C2SC3=CC(N(C)C)=CC=C3NC2=C1 QTWZICCBKBYHDM-UHFFFAOYSA-N 0.000 claims description 7
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000001931 aliphatic group Chemical group 0.000 claims description 5
- 230000010933 acylation Effects 0.000 claims description 4
- 238000005917 acylation reaction Methods 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 7
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims 6
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 claims 2
- 230000006196 deacetylation Effects 0.000 claims 2
- 238000003381 deacetylation reaction Methods 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 221
- 239000000203 mixture Substances 0.000 description 105
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 61
- 201000010099 disease Diseases 0.000 description 59
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
- 102000013498 tau Proteins Human genes 0.000 description 36
- 108010026424 tau Proteins Proteins 0.000 description 36
- 239000000243 solution Substances 0.000 description 35
- 230000035484 reaction time Effects 0.000 description 31
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 27
- 239000012535 impurity Substances 0.000 description 27
- 238000003756 stirring Methods 0.000 description 26
- 238000001914 filtration Methods 0.000 description 24
- 239000007787 solid Substances 0.000 description 23
- 229940037201 oris Drugs 0.000 description 21
- 238000011321 prophylaxis Methods 0.000 description 20
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 19
- 239000005457 ice water Substances 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- 201000011240 Frontotemporal dementia Diseases 0.000 description 16
- 238000009472 formulation Methods 0.000 description 16
- 229950000688 phenothiazine Drugs 0.000 description 15
- 239000011541 reaction mixture Substances 0.000 description 15
- 238000001816 cooling Methods 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 13
- 239000000546 pharmaceutical excipient Substances 0.000 description 13
- 230000009467 reduction Effects 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 241000711549 Hepacivirus C Species 0.000 description 12
- 241000710886 West Nile virus Species 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000011874 heated mixture Substances 0.000 description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 238000007281 aminoalkylation reaction Methods 0.000 description 10
- 239000012298 atmosphere Substances 0.000 description 10
- 239000007795 chemical reaction product Substances 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 238000010438 heat treatment Methods 0.000 description 10
- 201000004792 malaria Diseases 0.000 description 10
- 241000725303 Human immunodeficiency virus Species 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 229910052751 metal Inorganic materials 0.000 description 9
- 239000002184 metal Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 8
- 201000002832 Lewy body dementia Diseases 0.000 description 8
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 8
- 208000018737 Parkinson disease Diseases 0.000 description 8
- 208000034799 Tauopathies Diseases 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 239000011651 chromium Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000012279 sodium borohydride Substances 0.000 description 8
- 229910000033 sodium borohydride Inorganic materials 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- DZMADJOMDHBWJN-UHFFFAOYSA-N 1-[3,7-bis(methylamino)phenothiazin-10-yl]ethanone Chemical compound C1=C(NC)C=C2SC3=CC(NC)=CC=C3N(C(C)=O)C2=C1 DZMADJOMDHBWJN-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229910052804 chromium Inorganic materials 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- WOSISLOTWLGNKT-UHFFFAOYSA-L iron(2+);dichloride;hexahydrate Chemical compound O.O.O.O.O.O.Cl[Fe]Cl WOSISLOTWLGNKT-UHFFFAOYSA-L 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- VUWDHXCPXJCIJQ-UHFFFAOYSA-N 1-(3,7-dinitrophenothiazin-10-yl)ethanone Chemical compound [O-][N+](=O)C1=CC=C2N(C(=O)C)C3=CC=C([N+]([O-])=O)C=C3SC2=C1 VUWDHXCPXJCIJQ-UHFFFAOYSA-N 0.000 description 6
- ALJHHTHBYJROOG-UHFFFAOYSA-N 7-(dimethylamino)phenothiazin-3-one Chemical compound C1=CC(=O)C=C2SC3=CC(N(C)C)=CC=C3N=C21 ALJHHTHBYJROOG-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 206010034010 Parkinsonism Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000032859 Synucleinopathies Diseases 0.000 description 6
- 230000000397 acetylating effect Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000003610 charcoal Substances 0.000 description 6
- 229910052802 copper Inorganic materials 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
- 208000005176 Hepatitis C Diseases 0.000 description 5
- 241000222722 Leishmania <genus> Species 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- BZORFPDSXLZWJF-UHFFFAOYSA-N N,N-dimethyl-1,4-phenylenediamine Chemical compound CN(C)C1=CC=C(N)C=C1 BZORFPDSXLZWJF-UHFFFAOYSA-N 0.000 description 5
- 208000030852 Parasitic disease Diseases 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000000415 inactivating effect Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000004845 protein aggregation Effects 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 230000021736 acetylation Effects 0.000 description 4
- 238000006640 acetylation reaction Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 230000002567 autonomic effect Effects 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 208000005135 methemoglobinemia Diseases 0.000 description 4
- 208000027061 mild cognitive impairment Diseases 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 4
- 208000028172 protozoa infectious disease Diseases 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 241000894007 species Species 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 3
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 3
- KCSURCKZGJUTCH-UHFFFAOYSA-N 3,7-dinitro-10h-phenothiazine Chemical compound C1=C([N+]([O-])=O)C=C2SC3=CC([N+](=O)[O-])=CC=C3NC2=C1 KCSURCKZGJUTCH-UHFFFAOYSA-N 0.000 description 3
- 208000000230 African Trypanosomiasis Diseases 0.000 description 3
- 206010001935 American trypanosomiasis Diseases 0.000 description 3
- 208000024699 Chagas disease Diseases 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 3
- 241000223960 Plasmodium falciparum Species 0.000 description 3
- 102000019355 Synuclein Human genes 0.000 description 3
- 108050006783 Synuclein Proteins 0.000 description 3
- 201000005485 Toxoplasmosis Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011260 aqueous acid Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960003677 chloroquine Drugs 0.000 description 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 201000006592 giardiasis Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 208000029080 human African trypanosomiasis Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229910052745 lead Inorganic materials 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 201000002612 sleeping sickness Diseases 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 229910052718 tin Inorganic materials 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- 235000005074 zinc chloride Nutrition 0.000 description 3
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 2
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 2
- FCOLCILVZULVQA-UHFFFAOYSA-N 1-(3,7-diaminophenothiazin-10-yl)ethanone Chemical compound NC1=CC=C2N(C(=O)C)C3=CC=C(N)C=C3SC2=C1 FCOLCILVZULVQA-UHFFFAOYSA-N 0.000 description 2
- VXCIIQBCINCRNF-UHFFFAOYSA-N 1-(3,7-diaminophenothiazin-10-yl)ethanone;dihydrochloride Chemical compound Cl.Cl.NC1=CC=C2N(C(=O)C)C3=CC=C(N)C=C3SC2=C1 VXCIIQBCINCRNF-UHFFFAOYSA-N 0.000 description 2
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 2
- JHWIEAWILPSRMU-UHFFFAOYSA-N 2-methyl-3-pyrimidin-4-ylpropanoic acid Chemical compound OC(=O)C(C)CC1=CC=NC=N1 JHWIEAWILPSRMU-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- MBAIAYFVTLBVNX-UHFFFAOYSA-N 3-n,7-n-dimethyl-10h-phenothiazine-3,7-diamine Chemical compound C1=C(NC)C=C2SC3=CC(NC)=CC=C3NC2=C1 MBAIAYFVTLBVNX-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 239000007848 Bronsted acid Substances 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 229910017852 NH2NH2 Inorganic materials 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
- 241000223821 Plasmodium malariae Species 0.000 description 2
- 241001505293 Plasmodium ovale Species 0.000 description 2
- 241000223810 Plasmodium vivax Species 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000223104 Trypanosoma Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 description 2
- 229960003159 atovaquone Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940068911 chloride hexahydrate Drugs 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000020176 deacylation Effects 0.000 description 2
- 238000005947 deacylation reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- VOAPTKOANCCNFV-UHFFFAOYSA-N hexahydrate;hydrochloride Chemical compound O.O.O.O.O.O.Cl VOAPTKOANCCNFV-UHFFFAOYSA-N 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 2
- 229960005179 primaquine Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- CBBMGBGDIPJEMI-UHFFFAOYSA-N thionine cation Chemical class C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 CBBMGBGDIPJEMI-UHFFFAOYSA-N 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- SARMGXPVOFNNNG-UHFFFAOYSA-N 1-[amino-(4-chloroanilino)methylidene]-2-propan-2-ylguanidine;hydron;chloride Chemical compound Cl.CC(C)N=C(N)N=C(N)NC1=CC=C(Cl)C=C1 SARMGXPVOFNNNG-UHFFFAOYSA-N 0.000 description 1
- XQVRXJGJEWXBDH-UHFFFAOYSA-N 2,2-dimethylheptan-3-yl nitrite Chemical compound CCCCC(C(C)(C)C)ON=O XQVRXJGJEWXBDH-UHFFFAOYSA-N 0.000 description 1
- ZXVONLUNISGICL-UHFFFAOYSA-N 4,6-dinitro-o-cresol Chemical group CC1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O ZXVONLUNISGICL-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 241000256186 Anopheles <genus> Species 0.000 description 1
- 241000974482 Aricia saepiolus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 101100328518 Caenorhabditis elegans cnt-1 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000179197 Cyclospora Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 241000243234 Encephalitozoon Species 0.000 description 1
- 241000596569 Encephalitozoon intestinalis Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000289695 Eutheria Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 241000222738 Leishmania aethiopica Species 0.000 description 1
- 241000222697 Leishmania infantum Species 0.000 description 1
- 241000222732 Leishmania major Species 0.000 description 1
- 241000222734 Leishmania mexicana Species 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 241000289581 Macropus sp. Species 0.000 description 1
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 description 1
- 241000289390 Monotremata Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229940121743 Muscarinic receptor agonist Drugs 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 229910017833 NH2NH2.H2O Inorganic materials 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241001147660 Neospora Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241001126829 Nosema Species 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 241000289371 Ornithorhynchus anatinus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 241001442399 Trypanosoma brucei gambiense Species 0.000 description 1
- 241001442397 Trypanosoma brucei rhodesiense Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 241000289674 Vombatidae Species 0.000 description 1
- JXBCJUPBVRELNY-UHFFFAOYSA-N [7-(diethylamino)phenothiazin-3-ylidene]-diethylazanium Chemical compound C1=CC(N(CC)CC)=CC2=[S+]C3=CC(N(CC)CC)=CC=C3N=C21 JXBCJUPBVRELNY-UHFFFAOYSA-N 0.000 description 1
- PTOMEOCRFWOKHY-UHFFFAOYSA-N [Br-].CC1=CC=CC=CC=C[SH+]1 Chemical compound [Br-].CC1=CC=CC=CC=C[SH+]1 PTOMEOCRFWOKHY-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- RMRFFCXPLWYOOY-UHFFFAOYSA-N allyl radical Chemical compound [CH2]C=C RMRFFCXPLWYOOY-UHFFFAOYSA-N 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940010635 chloroquine / proguanil Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- SFQOCJXNHZJOJN-UHFFFAOYSA-H dialuminum;dioxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=S.[O-]S([O-])(=O)=S.[O-]S([O-])(=O)=S SFQOCJXNHZJOJN-UHFFFAOYSA-H 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000003619 fibrillary effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- LGDPTPLJZGPOJL-UHFFFAOYSA-N n,n-dimethyl-2-nitrosoaniline Chemical compound CN(C)C1=CC=CC=C1N=O LGDPTPLJZGPOJL-UHFFFAOYSA-N 0.000 description 1
- 239000007783 nanoporous material Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000002832 nitroso derivatives Chemical class 0.000 description 1
- 230000009635 nitrosylation Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000005691 oxidative coupling reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 229940118768 plasmodium malariae Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 229940066767 systemic antihistamines phenothiazine derivative Drugs 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000001016 thiazine dye Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000000083 urinary anti-infective agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B21/00—Thiazine dyes
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
- C09B67/0096—Purification; Precipitation; Filtration
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
- C09B67/0097—Dye preparations of special physical nature; Tablets, films, extrusion, microcapsules, sheets, pads, bags with dyes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81962706P | 2006-07-11 | 2006-07-11 | |
| EP07733509.9A EP2057136B1 (en) | 2006-07-11 | 2007-07-10 | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2457904T3 true DK2457904T3 (en) | 2015-01-12 |
Family
ID=38669650
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11173334.1T DK2457904T3 (en) | 2006-07-11 | 2007-07-10 | Methods for the synthesis and / or purification of the compounds diaminophenothiazinium |
| DK11173338.2T DK2457905T3 (en) | 2006-07-11 | 2007-07-10 | Methods for the synthesis and / or purification of diaminophenothiaziniumforbindelser |
| DK16173815.8T DK3121169T3 (da) | 2006-07-11 | 2007-07-10 | Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser |
| DK07733509.9T DK2057136T3 (da) | 2006-07-11 | 2007-07-10 | Fremgangsmåde til syntese og/eller oprensning af diaminophenothiazinium forbindelser |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11173338.2T DK2457905T3 (en) | 2006-07-11 | 2007-07-10 | Methods for the synthesis and / or purification of diaminophenothiaziniumforbindelser |
| DK16173815.8T DK3121169T3 (da) | 2006-07-11 | 2007-07-10 | Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser |
| DK07733509.9T DK2057136T3 (da) | 2006-07-11 | 2007-07-10 | Fremgangsmåde til syntese og/eller oprensning af diaminophenothiazinium forbindelser |
Country Status (16)
| Country | Link |
|---|---|
| US (10) | US7956183B2 (enExample) |
| EP (5) | EP3121169B1 (enExample) |
| JP (2) | JP5350237B2 (enExample) |
| CN (2) | CN101511803B (enExample) |
| AU (1) | AU2007274057B2 (enExample) |
| CA (1) | CA2657352C (enExample) |
| CY (1) | CY1118184T1 (enExample) |
| DK (4) | DK2457904T3 (enExample) |
| ES (4) | ES2912571T3 (enExample) |
| HU (1) | HUE030621T2 (enExample) |
| LT (1) | LT2457905T (enExample) |
| MY (2) | MY148145A (enExample) |
| PL (4) | PL2457904T3 (enExample) |
| PT (4) | PT2457904E (enExample) |
| SI (4) | SI2457905T1 (enExample) |
| WO (1) | WO2008007074A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2409683T3 (es) | 2004-09-23 | 2013-06-27 | Wista Laboratories Ltd. | Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT) |
| CN104606199B (zh) | 2006-03-29 | 2022-09-13 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物盐及其用途 |
| CN101511803B (zh) * | 2006-07-11 | 2012-10-31 | 维斯塔实验室有限公司 | 二氨基吩噻嗪*化合物的合成和/或纯化方法 |
| FR2903696B1 (fr) * | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
| PL2167095T3 (pl) * | 2007-06-19 | 2019-11-29 | Wista Lab Ltd | Związki fenotiazynowe do leczenia łagodnych zaburzeń poznawczych |
| DK2205245T3 (en) * | 2007-10-03 | 2015-09-28 | Wista Lab Ltd | Therapeutic use of diaminophenothiaziner |
| KR101774598B1 (ko) * | 2008-12-09 | 2017-09-04 | 인터퀴임, 에스.에이. | （6ｓ）（）５，６，７，８테트라하이드로-６-［프로필（２티에닐）에틸］아미노１나프톨（로티고틴）의 제조를 위한 공정 |
| JP5868955B2 (ja) | 2010-04-30 | 2016-02-24 | プロセッタ アンチバイラル インコーポレイテッド | 抗ウイルス化合物 |
| DE102010062810B4 (de) * | 2010-09-07 | 2014-03-13 | Immungenetics Ag | 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien |
| CA2827027C (en) | 2011-02-11 | 2019-06-04 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
| EP2699241B1 (en) | 2011-04-20 | 2016-07-27 | Prosetta Antiviral Inc. | Antiviral compounds |
| RU2535073C1 (ru) * | 2013-07-18 | 2014-12-10 | Федеральное государственное бюджетное учреждение науки "Научно-исследовательский институт общей реаниматологии имени В.А. Неговского" Российской академии медицинских наук | Способ лечения метгемоглобинемии |
| DK3033331T3 (da) | 2013-08-15 | 2018-04-30 | Eupharma Pty Ltd | Fremgangsmåde til oprensning af diaminophenothiazinium forbindelser |
| GB201317702D0 (en) * | 2013-10-07 | 2013-11-20 | Wista Lab Ltd | Methods of chemical synthesis of diaminophenothiazinium compounds including methylthioninium chloride (MTC) |
| FR3015481B1 (fr) * | 2013-12-20 | 2016-08-12 | Etat Francais Represente Par Le Delegue General Pour L'armement | Utilisation de composes de diaminophenothiazinium en tant qu'agents de prevention, reduction ou suppression d'une radiotoxicite |
| CN103864717B (zh) * | 2014-04-04 | 2015-11-11 | 山东理工大学 | 一种针状亚甲基白晶体的制备方法 |
| CA2976937C (en) | 2015-02-17 | 2023-04-04 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| DK3258938T3 (da) | 2015-02-17 | 2021-02-01 | Univ Arizona State | Phenothiazinanaloger som mitokondrie terapeutiske midler |
| GB201512678D0 (en) * | 2015-07-20 | 2015-08-26 | Wista Lab Ltd | Methods of chemical synthesis |
| CN105399703B (zh) * | 2015-12-15 | 2018-02-13 | 江苏恒润制药有限公司 | 一种亚甲基蓝的制备方法 |
| CN105541756B (zh) * | 2015-12-17 | 2018-02-09 | 陕西方舟制药有限公司 | 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法 |
| ITUA20163526A1 (it) * | 2016-05-17 | 2017-11-17 | Icrom Spa | Procedimento per la preparazione di composti diamminofenotiazinici ad elevato grado di purezza |
| PT3487505T (pt) | 2016-07-25 | 2023-06-07 | Wista Lab Ltd | Administração e dosagem de diaminofenotiazinas |
| US12570622B2 (en) | 2016-08-25 | 2026-03-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| US10745366B2 (en) | 2016-08-25 | 2020-08-18 | Arizon Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
| US11390605B2 (en) | 2016-08-25 | 2022-07-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Substituted pyrimidine compounds as multifunctional radical quenchers and their uses |
| GB201614834D0 (en) | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| GB201621817D0 (en) | 2016-12-21 | 2017-02-01 | Wista Lab Ltd | Methods of chemical synthesis |
| US11413240B2 (en) | 2016-12-29 | 2022-08-16 | Board Of Regents, The University Of Texas System | Methylene blue solution for the treatment of oral lesions |
| US10584201B2 (en) * | 2017-01-10 | 2020-03-10 | The Texas A&M University System | Methanesulfonic acid mediated solvent free synthesis of conjugated porous polymer networks |
| FR3063495B1 (fr) * | 2017-03-02 | 2019-04-05 | Provepharm Life Solutions | Procede de preparation de l’iodure de 3,7-bis(dimethylamino)phenothiazine-5-ylium |
| EP3375777A1 (en) | 2017-03-15 | 2018-09-19 | MIKROCHEM spol. s.r.o. | Method for preparation of 3,7-bis-(dimethylamino)-phenothiazin-5-ium chloride or bromide |
| JP7465861B2 (ja) | 2018-07-26 | 2024-04-11 | ウィスタ ラボラトリーズ リミテッド | 集団におけるジアミノフェノチアジンの最適化投与 |
| US11350853B2 (en) | 2018-10-02 | 2022-06-07 | Under Armour, Inc. | Gait coaching in fitness tracking systems |
| CN109337681B (zh) * | 2018-11-22 | 2020-05-08 | 南京工业大学 | 一种硫氮共掺杂的碳量子点的制备方法和应用 |
| TR201818670A2 (tr) | 2018-12-05 | 2020-06-22 | Eti Gida Sanayi Ve Ticaret Anonim Sirketi | Sızıntı yapmayan gıda dolgu maddesi depozitör sistemi. |
| US12215234B2 (en) * | 2019-09-21 | 2025-02-04 | RK Pharma Solutions LLC | Process for the purification of methylene blue |
| AU2021226188A1 (en) * | 2020-02-28 | 2022-11-10 | Dishman Carbogen Amcis Ltd | A process for the preparation of methylene blue |
| US12280062B2 (en) | 2021-02-24 | 2025-04-22 | Zydus Lifesciences Limited | Parenteral compositions comprising methylene blue |
| CN114656424B (zh) * | 2022-03-16 | 2023-06-27 | 深圳先进技术研究院 | 一种上转换长余辉化学发光成像纳米探针及其制备方法和应用 |
| CN114806211B (zh) * | 2022-03-16 | 2023-04-07 | 深圳先进技术研究院 | 一种疏水性亚甲蓝荧光染料及其制备方法和应用 |
| CN114507193B (zh) * | 2022-04-19 | 2022-06-24 | 英科隆生物技术（杭州）有限公司 | 电子媒介体天青c的提纯方法 |
| CN116947783B (zh) * | 2022-04-19 | 2026-04-17 | 英科隆生物技术（杭州）有限公司 | 一种电子媒介体的提纯方法 |
| WO2023202464A1 (zh) * | 2022-04-19 | 2023-10-26 | 英科隆生物技术（杭州）有限公司 | 一种电子媒介体的提纯方法 |
| CA3257856A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT) |
| CN114989113A (zh) * | 2022-06-01 | 2022-09-02 | 山东科源制药股份有限公司 | 一种药用亚甲基蓝的精制方法 |
| EP4590275A1 (en) | 2022-09-21 | 2025-07-30 | WisTa Laboratories Ltd. | Novel formulations and vehicles |
| EP4342451A1 (en) | 2022-09-22 | 2024-03-27 | Galenicum Health SLU | Pharmaceutical compositions and manufacturing methods thereof |
| US20240115579A1 (en) | 2022-09-22 | 2024-04-11 | Galenicum Health S.L.U. | Pharmaceutical compositions and manufacturing methods thereof |
| CN117447421A (zh) * | 2023-10-30 | 2024-01-26 | 上海沃凯生物技术有限公司 | 一种3,7-双-（二甲胺基）-吩噻嗪的合成方法 |
| IT202400006715A1 (it) * | 2024-03-26 | 2025-09-26 | Icrom S R L | Blu di metilene a ridotto contenuto di impurità n-nitroso-azzurro b e processo per ottenerlo |
| CN119823064B (zh) * | 2025-01-03 | 2025-12-30 | 仁合益康集团有限公司 | 一种亚甲蓝的制备方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1886C (de) | 1877-12-15 | 1877-12-15 | Basf Ag | Verfahren zur darstellung blauer farbstoffe aus dimethylanilin und anderen tertiaeren aromatischen monaminen |
| DE103147C (de) | 1898-06-07 | 1899-04-05 | Cohn Georg | Verfahren zur darstellung von acetylleukomethylenblau und -äthylenblau. |
| DE113721C (de) * | 1899-06-01 | 1900-09-28 | Verfahren zur Darstellung von Acidylderivaten der Leukothioninfarbstoffe | |
| US3395018A (en) | 1964-04-29 | 1968-07-30 | Du Pont | Light-sensitive color-forming composition |
| US3641016A (en) * | 1968-02-16 | 1972-02-08 | Egyt Gyogyszervegyeszeti Gyar | Thionine derivatives |
| DE2515966C3 (de) | 1975-04-11 | 1979-11-22 | Boehringer Mannheim Gmbh, 6800 Mannheim | Vorgefärbte Objektträger für die Blutunte rsuchung |
| US4003892A (en) | 1975-04-17 | 1977-01-18 | Serva-Entwicklungslabor V. Grothe & Co. | Method of separating thionine and its N-methyl derivatives from each other |
| US4212971A (en) | 1979-03-08 | 1980-07-15 | American Cyanamid Company | Process for preparing methylene blue |
| JPS6385644A (ja) * | 1986-09-30 | 1988-04-16 | Ricoh Co Ltd | 電子写真現像剤用トナ− |
| US5344928A (en) | 1991-04-26 | 1994-09-06 | Takeda Chemical Industries, Ltd. | Phenothiazine derivatives, their production and use |
| US6238931B1 (en) * | 1993-09-24 | 2001-05-29 | Biosite Diagnostics, Inc. | Fluorescence energy transfer in particles |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| EP0973383A4 (en) | 1997-01-21 | 2001-08-22 | American Nat Red Cross | INTRACELLULAR AND EXTRACELLULAR DECONTAMINATION OF WHOLE BLOOD AND BLOOD COMPONENTS WITH AMPHIPHILEN PHENOTHIAZINE-5-IUM DYES AND LIGHT |
| JP2000344685A (ja) | 1999-03-26 | 2000-12-12 | Bf Kenkyusho:Kk | アズールａ類似化合物によるアミロイドが蓄積する疾患の画像診断プローブおよびそれを含む画像診断用組成物 |
| IT1307270B1 (it) | 1999-10-12 | 2001-10-30 | Dideco Spa | Procedimento e dispositivo per la determinazione della concentrazionedi eparina in un campione di fluido. |
| JP2003531828A (ja) * | 2000-02-26 | 2003-10-28 | アドバンスト フォトダイナミック テクノロジーズ， インコーポレイテッド | 光感光性物質および界面活性剤を使用する、光力学的な細胞および無細胞生物の根絶 |
| FR2810318B1 (fr) | 2000-06-15 | 2005-09-23 | Laurent Galey | Derives de diamano-phenothiazine |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB2373787A (en) | 2001-03-08 | 2002-10-02 | Univ Central Lancashire | Phenothiazinium derivatives and their use to reduce pathogenic contaminants |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0113121D0 (en) | 2001-05-30 | 2001-07-18 | Univ Leeds | Biologically active photosensitisers |
| US7176308B2 (en) * | 2002-06-17 | 2007-02-13 | Verification Technologies, Inc. | Processes for preparing novel methylene blue derivative |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| AU2004295148A1 (en) * | 2003-11-28 | 2005-06-16 | Photopharmica Limited | Developments in biologically active methylene blue derivatives (2) |
| ES2409683T3 (es) | 2004-09-23 | 2013-06-27 | Wista Laboratories Ltd. | Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT) |
| JP5186212B2 (ja) | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
| CN104606199B (zh) | 2006-03-29 | 2022-09-13 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物盐及其用途 |
| CN101511803B (zh) | 2006-07-11 | 2012-10-31 | 维斯塔实验室有限公司 | 二氨基吩噻嗪*化合物的合成和/或纯化方法 |
| FR2903696B1 (fr) * | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
| CA2827027C (en) | 2011-02-11 | 2019-06-04 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
| PT3487505T (pt) | 2016-07-25 | 2023-06-07 | Wista Lab Ltd | Administração e dosagem de diaminofenotiazinas |
| GB201614834D0 (en) | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| GB201621817D0 (en) | 2016-12-21 | 2017-02-01 | Wista Lab Ltd | Methods of chemical synthesis |
| JP7465861B2 (ja) | 2018-07-26 | 2024-04-11 | ウィスタ ラボラトリーズ リミテッド | 集団におけるジアミノフェノチアジンの最適化投与 |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
-
2007
- 2007-07-10 CN CN2007800336078A patent/CN101511803B/zh active Active
- 2007-07-10 MY MYPI20090099A patent/MY148145A/en unknown
- 2007-07-10 WO PCT/GB2007/002570 patent/WO2008007074A2/en not_active Ceased
- 2007-07-10 SI SI200731836A patent/SI2457905T1/sl unknown
- 2007-07-10 EP EP16173815.8A patent/EP3121169B1/en active Active
- 2007-07-10 CN CN201210195299.1A patent/CN102718730B/zh active Active
- 2007-07-10 PL PL11173334T patent/PL2457904T3/pl unknown
- 2007-07-10 DK DK11173334.1T patent/DK2457904T3/en active
- 2007-07-10 ES ES16173815T patent/ES2912571T3/es active Active
- 2007-07-10 EP EP11173334.1A patent/EP2457904B1/en active Active
- 2007-07-10 JP JP2009518955A patent/JP5350237B2/ja active Active
- 2007-07-10 ES ES11173338.2T patent/ES2603783T3/es active Active
- 2007-07-10 EP EP11173338.2A patent/EP2457905B1/en not_active Revoked
- 2007-07-10 LT LTEP11173338.2T patent/LT2457905T/lt unknown
- 2007-07-10 ES ES11173334.1T patent/ES2529714T3/es active Active
- 2007-07-10 PL PL07733509T patent/PL2057136T3/pl unknown
- 2007-07-10 CA CA2657352A patent/CA2657352C/en active Active
- 2007-07-10 SI SI200732186T patent/SI3121169T1/sl unknown
- 2007-07-10 PT PT111733341T patent/PT2457904E/pt unknown
- 2007-07-10 EP EP07733509.9A patent/EP2057136B1/en active Active
- 2007-07-10 DK DK11173338.2T patent/DK2457905T3/en active
- 2007-07-10 DK DK16173815.8T patent/DK3121169T3/da active
- 2007-07-10 PL PL11173338T patent/PL2457905T3/pl unknown
- 2007-07-10 PT PT161738158T patent/PT3121169T/pt unknown
- 2007-07-10 PT PT111733382T patent/PT2457905T/pt unknown
- 2007-07-10 SI SI200731596T patent/SI2457904T1/sl unknown
- 2007-07-10 DK DK07733509.9T patent/DK2057136T3/da active
- 2007-07-10 PT PT77335099T patent/PT2057136E/pt unknown
- 2007-07-10 HU HUE11173338A patent/HUE030621T2/en unknown
- 2007-07-10 SI SI200731284T patent/SI2057136T1/sl unknown
- 2007-07-10 AU AU2007274057A patent/AU2007274057B2/en active Active
- 2007-07-10 EP EP22153513.1A patent/EP4063354A1/en active Pending
- 2007-07-10 MY MYPI2012001462A patent/MY162313A/en unknown
- 2007-07-10 PL PL16173815T patent/PL3121169T3/pl unknown
- 2007-07-10 ES ES07733509T patent/ES2421930T3/es active Active
- 2007-07-10 US US12/373,216 patent/US7956183B2/en active Active
-
2011
- 2011-05-31 US US13/149,164 patent/US8440821B2/en active Active
-
2013
- 2013-05-09 US US13/890,607 patent/US9382220B2/en active Active
- 2013-08-21 JP JP2013171087A patent/JP6243659B2/ja active Active
-
2016
- 2016-06-17 US US15/185,803 patent/US9675621B2/en active Active
- 2016-11-03 CY CY20161101128T patent/CY1118184T1/el unknown
-
2017
- 2017-06-09 US US15/619,199 patent/US9980971B2/en active Active
-
2018
- 2018-05-23 US US15/987,354 patent/US10525061B2/en active Active
-
2019
- 2019-11-15 US US16/685,420 patent/US11045477B2/en active Active
-
2021
- 2021-06-23 US US17/355,336 patent/US11878021B2/en active Active
-
2023
- 2023-12-08 US US18/533,515 patent/US20240115580A1/en not_active Abandoned
-
2025
- 2025-01-08 US US19/013,969 patent/US20250222006A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250222006A1 (en) | Methods of synthesis and/or purification of diaminophenothiazinium compounds | |
| AU2013200264B2 (en) | Methods of synthesis and/or purification of diaminophenothiazinium compounds | |
| HK1233267A1 (en) | Methods of synthesis and/or purification of diaminophenothiazinium compounds | |
| HK1233267B (en) | Methods of synthesis and/or purification of diaminophenothiazinium compounds | |
| HK1129675B (en) | Methods of synthesis and/or purification of diaminophenothiazinium compounds |